2,4-dichloro-1-(2-chloroethyl)benzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-dichloro-1-(2-chloroethyl)benzene
• 英文别名: 2,4-dichlorophenylethyl chloride；Benzene, 2,4-dichloro-1-(2-chloroethyl)-
• 化学式: C₈H₇Cl₃
• 分子量: 209.503
• InChiKey: BMDQWLPRIDRHJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2,4-二氯苯乙腈 、 2,4-dichloro-1-(2-chloroethyl)benzene 生成 2,4-Di-(2,4-dichlorphenyl)-butyronitril
  参考文献：
  名称：

  抗霉菌咪唑。2.1- [2-（芳烷基）-2-苯基乙基] -1H-咪唑的合成和抗霉菌性质。

  摘要：

  1- [2-（芳烷基）-2-苯基乙基] -1H-咪唑的合成从相应的苯基乙腈开始。通过连续的烷基化，转化为相应的酯，以及硼氢化钠-碘化锂还原，获得了β-苯基烷醇。这些醇被甲磺酸化，然后与咪唑在二甲基甲酰胺中回流，得到标题化合物，该化合物在体外对皮肤真菌，酵母菌，其他真菌和革兰氏阳性细菌具有活性。一些在体内还对白色念珠菌具有活性。

  DOI：

  10.1021/jm00221a032
• 作为产物：
  描述：

  2,2',4'-三氯苯乙酮 生成 2,4-dichloro-1-(2-chloroethyl)benzene
  参考文献：
  名称：

  GREINER, A., TETRAHEDRON LETT., 30,(1989) N7, C. 3547-3550

  摘要：

  DOI：

文献信息

• Chemoselective Homologation–Deoxygenation Strategy Enabling the Direct Conversion of Carbonyls into (<i>n+1</i>)-Halomethyl-Alkanes
  作者：Margherita Miele、Andrea Citarella、Thierry Langer、Ernst Urban、Martin Zehl、Wolfgang Holzer、Laura Ielo、Vittorio Pace

  DOI：10.1021/acs.orglett.0c02831

  日期：2020.10.2

  The sequential installation of a carbenoid and a hydride into a carbonyl, furnishing halomethyl alkyl derivatives, is reported. Despite the employment of carbenoids as nucleophiles in reactions with carbon-centered electrophiles, sp3-type alkyl halides remain elusive materials for selective one-carbon homologations. Our tactic levers on using carbonyls as starting materials and enables uniformly high

  据报道，将类胡萝卜素和氢化物顺序安装在羰基上，提供了卤代甲基烷基衍生物。尽管在与以碳为中心的亲电子试剂的反应中使用类胡萝卜素作为亲核试剂，sp 3型烷基卤化物仍然是用于选择性一碳同系物的难以捉摸的材料。我们的策略是利用羰基化合物作为起始原料，从而能够均匀地实现高收率和化学控制。该策略是灵活的，不仅限于类胡萝卜素。而且，各种类似碳负离子的物种可以充当亲核试剂，因此使其具有普遍的适用性。
• Pyridazine compounds and compositions containing the same
  申请人：Kowa Co., Ltd.

  公开号：US06348468B1

  公开（公告）日：2002-02-19

  This invention relates to pyridazine derivatives represented by the formula (1): wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (subsituted) aryl group, a (substituted) aryloxy group, a (substituted) nitrogen-containing heterocyclic ring residue, a (substituted) aminocarbonyl group or a lower alkylcarbonyl group, A represents a single bond, a lower alkylene group or a lower alkenylene group, X represents O or S, and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond, or salts thereof; and also to medicines containing them as effective ingredients. These compounds have excellent inhibitory activity against interleukin-1&bgr; production, and are useful as preventives and therapeutics for immune system diseases, inflammatory diseases, ischemic diseases and the like.

  这项发明涉及由式（1）表示的吡啶嗪衍生物： 其中R1代表（取代的）芳基，R2代表在4位被低烷氧基或低烷硫基取代的苯基，R3代表低烷氧基、卤代低烷基、低环烷基、（取代的）芳基、（取代的）芳氧基、（取代的）含氮杂环环残基、（取代的）氨基羰基或低烷基羰基，A代表单键、低烷基烯基或低烷烯基，X代表O或S，虚线表示4位和5位之间的碳-碳键为单键或双键，或其盐；以及含有它们作为有效成分的药物。这些化合物对白细胞介素-1β的产生具有出色的抑制活性，并可用作免疫系统疾病、炎症性疾病、缺血性疾病等的预防和治疗药物。
• Pyrrolo&lsqb;2,3-d&rsqb; pyrimidines as antiviral agents
  申请人：The Regents of the University of Michigan

  公开号：US06342501B1

  公开（公告）日：2002-01-29

  This invention relates to a novel class of 4,5,6,7-substituted non-nucleoside, non-phosphorylatable pyrrolo[2,3-d]pyrimidines which exhibit both significantly lower levels of cytotoxicity and superior antiviral activity than known nucleoside, non-nucleoside, and non-nucleoside, non-phosphorylatable pyrrolo[2,3-d]pyrimidine derivatives, particularly against human DNA viruses such as cytomegalovirus (HCMV) and herpes simplex virus type 1 (HSV-1). These compounds are represented by the following formula: wherein: R4 is —NR1R2 or oxo; R5 is —CN, or —CSNR1R2, or —CONR1R2; R6 is —H, or halo, or —NR1R2; wherein R1 and R2 are independently —H or an aliphatic group; and R7 is of the formula R3—Ar, wherein R3 is an aliphatic group and Ar is an unsubstituted aryl or an aryl independently substituted with halo, nitro, amino, or aliphatic groups; provided that when R5 is a —CN or —CSNH2, and R6 is a —H or —NH2, and Ar is a —C6H5 or a phenyl substituted with only one aliphatic group, R3 is an aliphatic group other than methyl such that —R3— is not a —CH2—; and pharmaceutically acceptable salts, prodrugs and derivatives thereof.

  这项发明涉及一类新型的4,5,6,7-取代的非核苷酸、非磷酸化的吡咯并［2,3-d］嘧啶化合物，这些化合物在人类DNA病毒如巨细胞病毒（HCMV）和单纯疱疹病毒1型（HSV-1）等方面表现出明显较低的细胞毒性和优越的抗病毒活性，优于已知的核苷酸、非核苷酸和非磷酸化的吡咯并［2,3-d］嘧啶衍生物。这些化合物由以下公式表示：其中：R4为—NR1R2或氧；R5为—CN，或—CSNR1R2，或—CONR1R2；R6为—H，或卤素，或—NR1R2；其中R1和R2独立地为—H或脂肪基；R7为R3—Ar的结构，其中R3为脂肪基，Ar为未取代芳基或独立取代有卤素、硝基、氨基或脂肪基的芳基；但当R5为—CN或—CSNH2，且R6为—H或—NH2，Ar为—C6H5或只取代一个脂肪基的苯基时，R3为甲基以外的脂肪基，使得—R3—不是—CH2—；以及其药用盐、前药和衍生物。
• [EN] INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3<br/>[FR] INHIBITEURS DE GLYCOGENE SYNTHASE KINASE 3
  申请人：CHIRON CORPORATION

  公开号：WO1999065897A1

  公开（公告）日：1999-12-23

  (EN) New pyrimidine or pyridine based compounds, having the structure (I), compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) $i(in vitro) and of treatment of GSK3 mediated disorders $i(in vivo) are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder immunodeficiency or cancer.(FR) L'invention concerne de nouveaux composés à base de pyrimidine ou de pyridine de la structure (I), des compositions et méthodes d'inhibition de l'activité de glycogène synthase kinase (GSK3) $i(in vitro) et de traitement de troubles induits par GSK3 $i(in vivo). Les méthodes, composés et compositions de la présente invention peuvent s'utiliser seuls ou en combinaison avec d'autres agents actifs du point de vue pharmacologique pour le traitement de troubles induits par l'activité de GSK3, tels que le diabète, la maladie d'Alzheimer et d'autres troubles neurodégénératifs, l'obésité, une maladie cardiovasculaire athéroscléreuse, l'hypertension artérielle essentielle, le syndrome des ovaires polkykystiques, le syndrome X, l'ischémie, le traumatisme cérébral, un trouble bipolaire, l'immunodéficience ou le cancer.

  新的以嘧啶或吡啶为基础的化合物，具有结构（I），提供了抑制糖原合成酶激酶（GSK3）$i（in vitro）活性和治疗GSK3介导的疾病$i（in vivo）的组合物和方法。本发明的方法、化合物和组合物可以单独使用，也可以与其他药理活性剂联合使用，用于治疗由GSK3活性介导的疾病，如糖尿病、阿尔茨海默病和其他神经退行性疾病、肥胖症、动脉粥样硬化心血管疾病、原发性高血压、多囊卵巢综合症、X综合症、缺血、创伤性脑损伤、双相情感障碍、免疫缺陷或癌症。
• Production of optically active 2-halo-1-(substituted phenyl)-ethanol and substituted styrene oxide
  申请人：Nihon Nohyaku Co., Ltd.

  公开号：EP0763513A2

  公开（公告）日：1997-03-19

  A process for producing optically active 2-halo-1-(substituted phenyl)ethanol of a formula (Ia) or optically active styrene oxide of a formula (Ib). The process comprises the steps of reacting a compound of a formula (II) with phthalic anhydride to give a compound of a formula (III), performing optical resolution on the resulting compound using an optically active organic amine as a resolving agent, and finally performing hydrolysis or alcoholysis on the optically resolved compound (Ia) or (Ib). The scheme of the above process is: wherein X represents a halogen atom, Y represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group or a C1-C6 haloalkoxy group, Z represents a hydrogen atom, a halogen atom or a C1-C6 alkyl group, n is 0 or an integer of 1 to 3 and m is 0 or an integer of 1 to 2. The resulting optically active compounds are useful as an intermediate for medicines.

  一种生产光学活性 2-卤代-1-(取代苯基)乙醇式(Ia)或光学活性氧化苯乙烯式(Ib)的工艺。该工艺包括以下步骤：将式（II）化合物与邻苯二甲酸酐反应生成式（III）化合物，使用光学活性有机胺作为分解剂对生成的化合物进行光学分解，最后对光学分解后的化合物（Ia）或（Ib）进行水解或醇解。上述工艺的方案为 其中 X 代表卤素原子，Y 代表氢原子、卤素原子、C1-C6 烷基、C1-C6 烷氧基、C1-C6 卤代烷基或 C1-C6 卤代烷氧基，Z 代表氢原子、卤素原子或 C1-C6 烷基，n 为 0 或 1 至 3 的整数，m 为 0 或 1 至 2 的整数。